Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539542 | 0.88 | TSHR (0.47) | USP2LMNACA1CA2ALDH1A1 | |
| SCHEMBL6540407 | 0.84 | CA1 (0.47) | CA1CA2ALDH1A1CA12CA9 | |
| SCHEMBL6540576 | 0.84 | USP2 (0.41) | USP2LMNAMTNR1AMTNR1BCA1 | |
| SCHEMBL6540191 | 0.82 | PTPN1 (0.47) | ALDH1A1 | |
| SCHEMBL6554075 | 0.81 | KMT2A (0.45) | LMNACA1CA2ALDH1A1TSHR | |
| SCHEMBL6677132 | 0.81 | HTT (0.42) | NAMPTALDH1A1 | |
| SCHEMBL6544777 | 0.81 | NAMPT (0.48) | NAMPTUSP2CA1CA2TSHR | |
| SCHEMBL6541135 | 0.81 | TSHR (0.50) | USP2LMNACA1CA2ALDH1A1 | |
| SCHEMBL6540879 | 0.81 | USP2 (0.47) | USP2LMNAMTNR1AMTNR1BCA1 | |
| SCHEMBL6541242 | 0.81 | CA1 (0.40) | USP2MTNR1AMTNR1BCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | NAMPT 4409/4885USP2 2077/4885LMNA 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.